EARNINGS: Arcontech profit and sales fall; Kromek profit tops forecast
The following is a round-up of earnings for London-listed companies, issued on Monday and not separately reported by Alliance News:
----------
Arcontech Group PLC - London-based provider of real-time financial market data and services - Pretax profit drops to £881,170 in the financial year ended June 30 from £987,390 the year prior. Revenue decreases by 12% to £2.8 million from £3.1 million with recurring revenue down by 4.7% and one-off revenues down by 94%. The dividend is maintained at 4.00 pence per share. Net cash nudges up 1.7% to £7.5 million from £7.4 million. The financial year saw the group add another major European bank to its customer base, but at the same time suffer the loss of a large long-standing customer. "We have a small market share so our potential for growth is significant. Our prospect list remains strong and we are in the process of introducing extensions to our products which we are confident will make us more competitive," company says in a statement. Chair Geoff Wicks says: "Our strategy will continue to focus on our core market, retaining and growing customer revenue is key. In order to do this we work closely with customers to understand their changing requirements which has led to the development of software that will allow our key products to be used more broadly across users at our customers. While this will have little impact on growth this year the longer-term potential is encouraging. We continue to assess accretive bolt-on acquisitions."
----------
Power Probe PLC - London-based producer of automotive electrical diagnostic tools for professional service technicians - Pretax profit falls 38% to USD2.8 million in the six months ended June 30 from USD4.6 million the year prior, as revenue drops 17% to USD17.7 million from USD21.2 million. Bottom line is hurt by more than doubled general & administration costs which surge to USD3.9 million from USD1.9 million, reflecting additional ongoing costs associated with operating as a publicly listed company together with continued investment in headcount. Power Probe expects new product launches to make a meaningful second half contribution. It boosts the interim dividend to 2.16 US cents from 1.33c. Chief Executive Chema Garcia says: "We enter the second half with a number of significant new products now launched, encouraging momentum in new territories and continued progress within the automotive manufacturer dealership channel. Alongside this, we are advancing our investment in US manufacturing capability in Charlotte and the systems and infrastructure needed to support the group's longer-term growth."
----------
Europa Oil & Gas Holdings PLC - UK and Ireland-focused oil and gas exploration, development and production company - Pretax loss narrows to £815,000 in the six months to June 30 from £874,000 the year prior. Revenue is flat at £1.5 million, cost of sales eases to £1.2 million from £1.3 million. Administrative expenses rise but this is offset by lower finance costs. Cash balance at June 30 is £2.8 million, up from £300,000 at the end of 2025. "Across the portfolio, our priorities for the second half of the year are clear: complete the Fuhai farm-out, prepare for the drilling of Barracuda, advance Cloughton and continue to seek partners for both Cloughton and Inishkea West. We remain debt-free, with a strengthened balance sheet, and are well placed to deliver what we believe could be a genuinely transformational catalyst for the company," says CEO Will Holland.
----------
Kromek Group PLC - Sedgefield, England-based detection technology supplier - Pretax profit is "slightly ahead of expectations" at £2.5 million in the financial year ended April 30, Kromek says, albeit down from £3.1 million the year prior. Revenue increases to £27.1 million from £26.5 million with Advanced Imaging revenue of £19.9 million and CBRN Detection revenue of £7.3 million. Gross margin dips to 63% from 81% due to revenue mix, including high-margin licensing revenue accounting for a higher proportion of revenue in 2025. CEO Arnab Basu says: "FY 2026 was a year of strong operational and commercial progress for Kromek. We delivered increased revenue, with significant underlying growth in Advanced Imaging and further growth in CBRN Detection, reflecting increased delivery on long-term customer programmes, new order wins and the continued expansion of our international distributor network." Looking ahead, Basu says Kromek enters the new financial year with "positive momentum, supported by a healthy order book, an encouraging commercial pipeline and strong engagement with customers across both divisions." Looks forward to the year ahead with "confidence".
----------
ATC Music Group PLC - London-based music talent management, live booking and merchandising firm previously called All Things Considered - Pretax loss narrows to £2.1 million in the six months ended June 30 from £2.3 million the year prior as revenue climbs to £30.6 million from £22.1 million. Representation revenue grows 39%, Services revenue rises 40% and Events revenue increases 29%. Basic and diluted losses per share total 7.29 pence versus 10.74p a year ago. Says it has established a solid foundation for future organic growth, supported by a large and visible pipeline of strategic acquisitions for FY26 and beyond. Trading momentum in the second half of the year has continued to grow, it adds.
----------
Fusion Antibodies PLC - Belfast-based contract researcher providing discovery, design and optimisation services for therapeutic antibodies - Pretax loss narrows to £1.1 million in the financial year ended March 31 from £1.6 million the year prior. Revenue climbs to £2.1 million from £2.0 million. Gross margin increases to 53% from 22%. Basic losses per share are 1.2 pence versus 1.7p. "FY2026 was another year of important progress for the company. We had revenue growth, a significant improvement in gross margin and a stronger cash position, despite the continued challenging market environment," says CEO Adrian Kinkaid. Says the global financial "instability and uncertainty" remains a challenge for the healthcare sector and is adversely impacting Fusion's performance in the first half of FY27. Despite the broader macro-environment, Fusion remains cautiously optimistic about the future.
----------
Copyright 2026 Alliance News Ltd. All Rights Reserved.